MétaCan
Menu
Back to cohort
Record W2563196695 · doi:10.1111/dom.12840

Metformin in adults with type 1 diabetes: <scp>D</scp> esign and methods of <scp>REducing</scp> with <scp>MetfOrmin V</scp> ascular <scp>A</scp> dverse <scp>L</scp> esions ( <scp>REMOVAL</scp> ): <scp>A</scp> n international multicentre trial

2016· article· en· W2563196695 on OpenAlexaff
John R. Petrie, Nish Chaturvedi, Ian Ford, Irene Hramiak, Alun D. Hughes, Alicia J. Jenkins, Barbara E.K. Klein, Ron Klein, Teik Chye Ooi, Peter Rossing, Naveed Sattar, Coen D.A. Stehouwer, Helen M. Colhoun

Bibliographic record

VenueDiabetes Obesity and Metabolism · 2016
Typearticle
Languageen
FieldMedicine
TopicDiabetes Management and Research
Canadian institutionsOttawa HospitalSt Joseph's Health Care
FundersSteno Diabetes Center CopenhagenMerck KGaABritish Heart FoundationJuvenile Diabetes Research Foundation United Kingdom
KeywordsMetforminMedicinePharmacologyType 2 diabetesDiabetes mellitusEndocrinology

Abstract

fetched live from OpenAlex

AIMS: Cardiovascular (CV) disease is a major cause of reduced life expectancy in type 1 diabetes (T1D). Intensive insulin therapy prevents CV complications but is constrained by hypoglycaemia and weight gain. Adjunct metformin reduces insulin dose requirement and stabilizes weight but there are no data on its cardiovascular effects. We have therefore initiated an international double-blind, randomized, placebo-controlled trial (REMOVAL: REducing with MetfOrmin Vascular Adverse Lesions in type 1 diabetes) to examine whether metformin reduces progression of atherosclerosis in adults with T1D. Individuals ≥40 years of age with T1D for ≥5 years are eligible if they have ≥3 of 10 specified CV risk factors. The enrolment target is 500 participants in 17 international centres. MATERIALS AND METHODS: After 12 weeks of single-blind placebo-controlled run-in, participants with ≥ 70% adherence are randomized to metformin or matching placebo for 3 years with insulin titrated towards HbA1c 7.0% (53 mmol/mol). The primary endpoint is progression of averaged mean far wall common carotid intima-media thickness (cIMT) measured by ultrasonography at baseline, 12, 24 and 36 months. This design provides 90% power to detect a mean difference of 0.0167 mm in cIMT progression between treatment arms (α = 0.05), assuming that up to 20% withdraw or discontinue treatment. Other endpoints include HbA1c, weight, LDL cholesterol, insulin requirement, progression of retinopathy, endothelial function and frequency of hypoglycaemia. CONCLUSION: REMOVAL is the largest clinical trial of adjunct metformin therapy in T1D to date and will provide clinically meaningful information on its potential to impact CV disease and other complications.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.011
metaresearch head score (Gemma)0.055
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch, Meta-epidemiology (narrow), Science and technology studies, Scholarly communication, Research integrity
Consensus categoriesMeta-epidemiology (narrow), Science and technology studies, Research integrity
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.377
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0110.055
Meta-epidemiology (narrow)0.0040.003
Meta-epidemiology (broad)0.0070.002
Bibliometrics0.0050.005
Science and technology studies0.0010.003
Scholarly communication0.0010.004
Open science0.0030.002
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.272
Teacher spread0.258 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations40
Published2016
Admission routes1
Has abstractyes

Explore more

Same venueDiabetes Obesity and MetabolismSame topicDiabetes Management and ResearchFrench-language works237,207